JP2020518669A - 非縮合三環式化合物 - Google Patents

非縮合三環式化合物 Download PDF

Info

Publication number
JP2020518669A
JP2020518669A JP2020511737A JP2020511737A JP2020518669A JP 2020518669 A JP2020518669 A JP 2020518669A JP 2020511737 A JP2020511737 A JP 2020511737A JP 2020511737 A JP2020511737 A JP 2020511737A JP 2020518669 A JP2020518669 A JP 2020518669A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
independently
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518669A5 (enExample
Inventor
ダブリュー． コンラディ，アンドレイ
ダブリュー． コンラディ，アンドレイ
ズ−リン タン リン，トレーシー
ズ−リン タン リン，トレーシー
Original Assignee
ビバーチェ セラピューティクス，インク．
ビバーチェ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビバーチェ セラピューティクス，インク．, ビバーチェ セラピューティクス，インク． filed Critical ビバーチェ セラピューティクス，インク．
Publication of JP2020518669A publication Critical patent/JP2020518669A/ja
Publication of JP2020518669A5 publication Critical patent/JP2020518669A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020511737A 2017-05-03 2018-05-02 非縮合三環式化合物 Pending JP2020518669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500937P 2017-05-03 2017-05-03
US62/500,937 2017-05-03
PCT/US2018/030721 WO2018204532A1 (en) 2017-05-03 2018-05-02 Non-fused tricyclic compounds

Publications (2)

Publication Number Publication Date
JP2020518669A true JP2020518669A (ja) 2020-06-25
JP2020518669A5 JP2020518669A5 (enExample) 2021-07-26

Family

ID=64016799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511737A Pending JP2020518669A (ja) 2017-05-03 2018-05-02 非縮合三環式化合物

Country Status (7)

Country Link
US (1) US11186554B2 (enExample)
EP (1) EP3618818A4 (enExample)
JP (1) JP2020518669A (enExample)
CN (1) CN111132673A (enExample)
AU (1) AU2018263921A1 (enExample)
CA (1) CA3062294A1 (enExample)
WO (1) WO2018204532A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503671A (ja) * 2022-01-14 2025-02-04 デウン ファーマシューティカル カンパニー リミテッド 癌細胞成長抑制効果を有する新規アミノベンゼン誘導体およびこれを有効成分として含む予防または治療用薬剤学的組成物
JP2025530470A (ja) * 2022-09-23 2025-09-11 ハンチョウ フェクダメッド シーオー．エルティーディー． リン酸化アリール構造を有する小分子化合物とその使用

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
WO2019113236A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CN109260200A (zh) * 2018-11-21 2019-01-25 南方科技大学 化合物dCTB在制备治疗癌性疼痛的药物中的应用
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
JP2022525186A (ja) * 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
AU2020257207B2 (en) * 2019-04-16 2026-06-04 Vivace Therapeutics, Inc. Bicyclic compounds
BR112021024108A2 (pt) * 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
US11458149B1 (en) * 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
EP4003983A1 (en) * 2019-07-29 2022-06-01 Basilea Pharmaceutica International AG 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2021224291A1 (en) * 2020-05-08 2021-11-11 Merck Patent Gmbh Tricyclic heterocycles useful as tead binders
US20240124406A1 (en) * 2020-06-03 2024-04-18 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
AR123656A1 (es) 2020-09-30 2022-12-28 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
BR112023014751A2 (pt) 2021-01-25 2023-10-03 Ikena Oncology Inc Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão
AU2022258968A1 (en) 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CN115594680A (zh) * 2021-07-07 2023-01-13 武汉人福创新药物研发中心有限公司（Cn） 一种tead抑制剂
CN113461643A (zh) * 2021-07-20 2021-10-01 韶远科技（上海)有限公司 一种4-甲基苯磺酸[(3-氟氧杂环丁烷-3-基)甲基]酯的合成方法
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023057371A1 (en) 2021-10-04 2023-04-13 Basilea Pharmaceutica International Ag, Allschwil 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US12030866B2 (en) 2021-12-23 2024-07-09 Springworks Therapeutics, Inc. 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD
WO2023116877A1 (zh) * 2021-12-24 2023-06-29 武汉人福创新药物研发中心有限公司 作为tead抑制剂的杂环化合物
WO2023143354A1 (zh) * 2022-01-30 2023-08-03 希格生科（深圳）有限公司 三环化合物及其应用
WO2023150619A2 (en) 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023204822A1 (en) * 2022-04-22 2023-10-26 Vivace Therapeutics, Inc. Phenyl phosphine oxide compounds and methods of use thereof
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2024092116A1 (en) 2022-10-26 2024-05-02 Ikena Oncology, Inc. Combination of tead inhibitors and egfr inhibitors and uses thereof
WO2024105610A1 (en) 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024173761A1 (en) 2023-02-17 2024-08-22 Ikena Oncology, Inc. Combinations comprising mek inhibitors for use in the treatment of cancer
CN120659608A (zh) 2023-02-23 2025-09-16 诺华股份有限公司 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
EP4669319A1 (en) 2023-02-23 2025-12-31 Novartis AG TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025088571A1 (en) 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
WO2025141118A1 (en) 2023-12-27 2025-07-03 Institut National de la Santé et de la Recherche Médicale Arylalkyloxyindole compounds and derivatives and their use
TW202547484A (zh) 2024-04-10 2025-12-16 瑞士商諾華公司 藥物組合及其用途
WO2026114957A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer
US20260146049A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20260146050A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
WO2026114918A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
JP2011190284A (ja) * 2003-08-29 2011-09-29 Exelixis Inc ｃ−Ｋｉｔ調節因子および使用方法
JP2014517016A (ja) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
WO2017079542A1 (en) * 2015-11-04 2017-05-11 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895027A (en) 1974-04-12 1975-07-15 Lilly Co Eli Process for preparing pyrazole-3-carboxylic acids
US3903106A (en) 1974-04-12 1975-09-02 Lilly Co Eli Pyrazole-3-carboxylic acids
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
US5066668A (en) 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
US4962119A (en) 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
FI902771A7 (fi) 1989-06-09 1990-12-10 Warner Lambert Co Menetelmä anti-inflammatoristen 1,3,4-tiadiatsolien ja 1,3,4-oksadiatsolien valmistamiseksi
US5114958A (en) 1991-05-09 1992-05-19 Warner-Lambert Company 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
US5670526A (en) 1995-12-21 1997-09-23 Otsuka Pharmaceutical Co., Ltd. 1,3,4-oxadiazoles
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6211209B1 (en) 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
JP2002534515A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー １−複素環置換されたジアリールアミン
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
HUP0202381A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1
EA200802050A1 (ru) 2006-04-19 2009-04-28 Лаборатуар Сероно Са Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
US20150157584A1 (en) 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
US9994577B2 (en) 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
MX2017012738A (es) 2015-04-03 2017-11-15 Bristol Myers Squibb Co Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
WO2017058716A1 (en) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
WO2019113236A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP2011190284A (ja) * 2003-08-29 2011-09-29 Exelixis Inc ｃ−Ｋｉｔ調節因子および使用方法
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
JP2014517016A (ja) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
WO2017079542A1 (en) * 2015-11-04 2017-05-11 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
JP2018532805A (ja) * 2015-11-04 2018-11-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503671A (ja) * 2022-01-14 2025-02-04 デウン ファーマシューティカル カンパニー リミテッド 癌細胞成長抑制効果を有する新規アミノベンゼン誘導体およびこれを有効成分として含む予防または治療用薬剤学的組成物
JP7869861B2 (ja) 2022-01-14 2026-06-03 デウン ファーマシューティカル カンパニー リミテッド 癌細胞成長抑制効果を有する新規アミノベンゼン誘導体およびこれを有効成分として含む予防または治療用薬剤学的組成物
JP2025530470A (ja) * 2022-09-23 2025-09-11 ハンチョウ フェクダメッド シーオー．エルティーディー． リン酸化アリール構造を有する小分子化合物とその使用

Also Published As

Publication number Publication date
EP3618818A1 (en) 2020-03-11
CN111132673A (zh) 2020-05-08
US11186554B2 (en) 2021-11-30
AU2018263921A1 (en) 2019-12-05
US20200062721A1 (en) 2020-02-27
EP3618818A4 (en) 2020-12-09
WO2018204532A1 (en) 2018-11-08
CA3062294A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
US11186554B2 (en) Non-fused tricyclic compounds
EP3691623B1 (en) Benzosulfonyl compounds
CN114072207B (zh) 双环化合物
EP4271674B1 (en) Carboxy-benzimidazole glp-1r modulating compounds
US12180197B2 (en) GLP-1R modulating compounds
JP7482861B2 (ja) 二環式化合物
EP4691554A2 (en) Glp-1r modulating compounds
US11661403B2 (en) Oxadiazole compounds
CN115279368B (zh) 杂芳基化合物
TWI786639B (zh) B型肝炎核心蛋白質調節劑
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
AU2018213637A1 (en) LSD1 inhibitor and preparation method and application thereof
EP3257848A1 (en) Compounds and compositions for modulating egfr activity
US20230075856A1 (en) Cyclic sulfamide compounds for treatment of hbv
AU2023225437A1 (en) Indazole compound and pharmaceutical use thereof
HK40049153A (en) Hepatitis b core protein modulators
HK40068715A (en) Bicyclic compounds
HK40068715B (en) Bicyclic compounds
BR112018005178B1 (pt) Compostos moduladores de proteína base de hepatite b, composições farmacêuticas compreendendo tais compostos e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221109